Empagliflozin Reversal of Arterial StiffnEss in Aging

Summary

Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.

Timeline

Start

2024-08-18

Primary completion

2028-10-31

Completion

2029-02-28

Drugs

Indications